Strategic focus Target late-stage, de-risked life sciences assets with proven safety and efficacy to align with New Rhein’s investment thesis, presenting opportunities to upsell strategic exits and co-development potential.

Portfolio growth Highlight companies with clear paths to commercialization and payer value to fit New Rhein’s goal of generating capital gains through strategic exits, suggesting collaboration on regulatory milestones and market access strategies.

Tech-enabled scale Emphasize data-driven diligence tools, regulatory and CMC capabilities, and potential for operational support to accelerate portfolio growth, appealing to New Rhein’s hands-on approach.

Key personnel access Engage senior pharma and MedTech executives or proven dealmakers who can bolster sourcing, due diligence, and M&A activity, aligning with New Rhein’s experienced leadership profile.

Successful exits Present evidenced exit pathways, including strategic partnerships, acquisitions, or licensing deals, that demonstrate tangible return potential and align with New Rhein’s emphasis on strategic exits.